非奈利酮在心力衰竭中的疗效与安全性:按衰弱状态分层的FINEARTS-HF预设分析
FINEARTS-HF预设分析纳入5952例HFmrEF或HFpEF患者,按Rockwood衰弱指数分为I–III级。非奈利酮对主要复合终点(心血管死亡和总恶化HF事件)的效应不随衰弱分级显著改变(交互P=0.77),且低血压、肌酐升高、高钾血症或低钾血症风险在各衰弱分级间无差异。
要点
- 衰弱分级越高,主要终点风险越高:II级RR 1.88,III级RR 3.86(vs I级)。
- 非奈利酮对主要终点的效应不随衰弱分级显著改变(交互P=0.77)。
- 非奈利酮的安全性事件(低血压、肌酐升高、高钾/低钾)在各衰弱分级间无差异。
核心结论
- 在FINEARTS-HF中,非奈利酮降低总恶化HF事件和心血管死亡风险并改善症状,该效应不受衰弱状态影响。
- 非奈利酮对低血压、肌酐升高、高钾血症或低钾血症的影响在各衰弱分级间无差异。
研究设计与样本
- FINEARTS-HF的预设二次分析,III期随机临床试验,覆盖37个国家653个中心。
- 6001例随机,5952例可计算衰弱指数;平均年龄72.0岁(SD 9.6),男性3241例(54.4%)。
- 纳入NYHA II–IV级、LVEF≥40%、有结构性心脏病证据且利钠肽升高的HF患者,2020年9月至2023年1月随机。
- 干预为每日一次非奈利酮或安慰剂加常规治疗;主要终点为心血管死亡和总恶化HF事件的复合终点。
- 衰弱采用Rockwood累积缺陷法测量:I级(FI≤0.210)1588例(26.7%),II级(FI 0.211–0.310)2141例(36.0%),III级(FI≥0.311)2223例(37.3%)。
主要发现
- 与I级衰弱相比,II级和III级衰弱患者主要终点风险更高:未校正RR 1.88(95%CI 1.54–2.28)和3.86(95%CI 3.22–4.64)。
- 非奈利酮对主要终点的效应在各衰弱分级间无显著差异:I级RR 1.07(95%CI 0.77–1.49),II级RR 0.66(95%CI 0.52–0.83),III级RR 0.91(95%CI 0.76–1.07),交互P=0.77。
- 衰弱分级未改变非奈利酮对主要终点各组分、全因死亡或KCCQ总症状评分改善的效应。
- 非奈利酮与安慰剂相比,低血压、肌酐升高、高钾血症或低钾血症的发生风险在各衰弱分级间无差异。
临床怎么用
- 对HFmrEF或HFpEF患者,衰弱状态不应作为排除非奈利酮治疗的理由。
- 衰弱分级较高的患者主要终点风险更高,需更积极管理HF。
- 非奈利酮的安全性事件在各衰弱分级间无差异,但仍需按常规监测低血压、肾功能和血钾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. OBJECTIVE: To examine the efficacy and safety of finerenone, compared with placebo, according to frailty status in patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or with HF and preserved ejection fraction (HFpEF). DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of a phase 3 randomized clinical trial, the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF), conducted across 653 sites in 37 countries. Patients with HF with New York Heart Association functional class II through IV, a left ventricular ejection fraction of 40% or higher, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized between September 2020 and January 2023. Data analysis was conducted from October 1 to November 30, 2024. INTERVENTION: Addition of once-daily finerenone or placebo to usual therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total worsening HF events. Frailty was measured using the Rockwood cumulative deficit approach. RESULTS: Of the 6001 patients randomized in FINEARTS-HF, a frailty index (FI) was calculable in 5952 patients (mean [SD] age, 72.0 [9.6] years; 3241 [54.4%] male). In total, 1588 patients (26.7%) had class I frailty (FI ≤0.210 [not frail]), 2141 (36.0%) had class II frailty (FI 0.211-0.310 [more frail]), and 2223 (37.3%) had class III frailty (FI ≥0.311 [most frail]). Compared with patients with class I frailty, those with class II and III frailty had a higher risk of the primary outcome (unadjusted rate ratio [RR], 1.88 [95% CI, 1.54-2.28] for class II and 3.86 [95% CI, 3.22-4.64] for class III). The effect of finerenone on the primary outcome did not vary significantly by frailty class (class I: RR, 1.07 [95% CI, 0.77-1.49]; class II: RR, 0.66 [95% CI, 0.52-0.83]; class III: RR, 0.91 [95% CI, 0.76-1.07]; P for interaction = .77). Frailty class did not modify the effects of finerenone on the components of the primary outcome, all-cause death, or improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score. The effects of finerenone, compared with placebo, on experiencing hypotension, elevated creatinine level, hyperkalemia, or hypokalemia did not differ by frailty class. CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms; these effects were not modified by frailty status. In addition, the effects of finerenone on experiencing hypotension, elevated creatinine level, hyperkalemia, or hypokalemia did not differ by frailty status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- Butt, Jhund, Henderson, et al. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40531488. doi:10.1001/jamacardio.2025.1775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。